Management of chemotherapy-associated febrile neutropenia.
The development of febrile neutropenia during a course of chemotherapy is not only a life-threatening complication, it can also lead to a decision to reduce chemotherapy intensity in subsequent treatment cycles, thus putting patient outcomes at risk. Although there are strategies available for the primary prevention of febrile neutropenia, these are not widely used in the UK management of breast cancer. It is, therefore, paramount to have a well thought out and rigorously implemented care protocol for febrile neutropenia, involving patients, family/carers and health-care professionals in both primary and secondary care, to ensure early detection and effective management.
Cameron
D
D
NCRN Coordinating Centre, University of Leeds, MacMillan Wing, Fairbairn House, 71-75 Clarendon Road, Leeds LS2 9PH, UK. d.cameron@ncrn.org.uk
D000970:Antineoplastic Agents / Q000009:adverse effects*; D005334:Fever / Q000139:chemically induced / Q000628:therapy*; D006801:Humans; D009503:Neutropenia / Q000139:chemically induced / Q000628:therapy*; D010343:Patient Admission; D012017:Referral and Consultation
D000970:Antineoplastic Agents